The data were presented December 9, 2023, during the 65th American Society of Hematology Annual Meeting and Exposition in San Diego, California.
Updated results from the primary analysis of the phase 3 COMMANDS trial (NCT03682536), continue to show benefits of luspatercept (Reblozyl) compared with epoetin alfa for treatment of anemia in patients with myelodysplastic syndromes (MDS), among patients not previously treated with erythropoiesis stimulating agents (ESAs) but who may require red blood cell transfusions.
The data were presented December 9, 2023, during the 65th American Society of Hematology Annual Meeting and Exposition in San Diego, California. These results updated the interim analysis presented at the American Society of Clinical Oncology (ASCO), which led to approval for luspatercept for this group of patients in late August.
“These data from the COMMANDS trial, including additional patients and longer follow-up from the data shown at ASCO, confirm the positive outcome of the interim analysis with superior efficacy and durability compared to ESAs and exemplify how [luspatercept] may impact the treatment of anemia related to MDS,” Guillermo Garcia-Manero, MD, lead investigator and Chief of the Section of Myelodysplastic Syndromes at The University of Texas MD Anderson Cancer Center, said in a statement. “Further, beyond the intent-to-treat population, the analysis confirms that [luspatercept] demonstrated clinical benefit across subgroups.”
The treatment is being developed and commercialized through a global collaboration with Merck as of November 2021 and awaits action from the European Commission.
Results. The analysis presented at ASH involved 363 patients randomized 1:1 to receive luspatercept and epoetin alfa. Results presented were from the analysis of the intent-to-treat population, with data cut off March 31, 2023, and a median treatment uration of 51.3 (3–196) and 37.0 (1–202) weeks for luspatercept and epoetin alfa, and a median follow up of 17.2 (1–46) and 16.9 (0–46) months, respectively. The treatment length was approximately 10 weeks longer at this analysis than at the ASCO presentation. Results showed:
Common treatment-emergent adverse events in at least 10% of patients were diarrhea, fatigue, COVID-19, hypertension, dyspnea, nausea, peripheral edema, asthenia, dizziness, anemia, back pain and headache. Rates of patient-reported fatigue and asthenia decreased over time. The share of patients who progressed to acute myeloid leukemia and total deaths were similar between arms of the study.
Subanalyses confirmed patients taking luspatercept had similar or better transfusion independence than those taking epoetin alfa across a range of clinical subgroups, including mutational profile, Molecular International Prognostic Scoring System (IPSS-M) status, ring sideroblast status, transfusion burden and serum erythropoietin (sEPO) level. Duration of transfusion independent favored luspatercept across all subgroups as well, according to the results.
Reference
Garcia-Manero G, Platzbecker U, Santini V, et al. Efficacy and safety of luspatercept versus epoetin alfa in erythropoiesis-stimulating agent (ESA)-naive patients with transfusion-dependent lower-risk myelodysplastic syndromes: full analysis of the COMMANDS trial. Presented at: 65th American Society of Hematology Annual Meeting and Exposition, San Diego, CA: December 9-12, 2023; Abstr 193. https://doi.org/10.1182/blood-2023-178596
NGS-Based Test Accurately Detects Post–Allo-HSCT Relapse in AML, MDS
February 21st 2025The next-generation sequencing (NGS)–based AlloHeme test accurately predicted relapse following allogeneic hematopoietic stem cell transplantation (allo-HSCT) in acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS).
Read More
Characterizing Patients With MDS Who Undergo Allo-HSCT
January 29th 2025Patients with myelodysplastic syndromes (MDS) who undergo allogeneic hematopoietic stem cell transplantation (allo-HSCT) are older and face worse outcomes compared with non-MDS patients, according to posters presented at the 2024 American Society of Hematology meeting.
Read More
Treosulfan Regimen Approved for Allo-HSCT Conditioning in AML/MDS
January 23rd 2025The FDA approved treosulfan in combination with fludarabine as preparation for allogeneic hematopoietic stem cell transplantation (allo-HSCT) in adult and pediatric patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS).
Read More
Unmet Needs Remain in Secondary AML Following Treatment With HMAs
January 18th 2025The study demonstrated a poor prognosis overall for patients with acute myeloid leukemia (AML) who were previously treated with hypomethylating agents (HMAs) for myeloid neoplasms such as myelodysplastic syndromes.
Read More